2025

• MSD announced global phase 3 results using Hybrozyme™ Technology for their subcutaneous pembrolizumab
• Executed Hybrozyme™ Technology license agreement with AstraZeneca for 3 oncology products
• Listed on the KOSDAQ Rising Star Hall of Fame
• Subsidiaries ‘Altos Biologics’ and ‘Alteogen Healthcare’ merged to ‘Alteogen Biologics’
• EYLUXVI(ALT-L9, Eylea biosimilar) granted Marketing Authorization (MA) by the European Commission (EC)
• MSD subcutaneous Keytruda using Hybrozyme™ Technology approval in FDA and EC
• Innovative Pharmaceutical Company: Received the Minister’s Commendation (MOHW)
• Advancement of Health Technology: Received the Minister’s Commendation (MOHW)
• Development of the Bio Industry (Export Promotion): Received the Minister’s Commendation (MOTIE)

2024

• Ceres F&D name changed to ‘Alteogen Healthcare’
• Executed amendment to Hybrozyme™ Technology license agreement with MSD for pembrolizumab
• Received Notice of Allowance from USPTO for ‘ALT-B5’, long-acting acromegaly treatment
• Received milestone as completion of phase 3 trial in China of Herceptin® biosimilar ‘ALT-L2’ by Qilu Pharmaceutical
• Submission of MAA to EMA for Eylea® biosimilar ‘ALT-L9’
• Received Notice of BLA to MFDS Tergase®, stand-alone recombinant hyaluronidase product
• Executed Hybrozyme™ Technology license agreement with Sandoz AG for multiple products
• Launched Herceptin® biosimilar ‘ALT-L2’ in China
• Approval of IND to DCGI for Phase 2 trial of long-acting human growth hormone ‘ALT-P1’
• Selected as ‘2024 KOSDAQ Rising Star’ (KRX)
• Executed Hybrozyme™ Technology license agreement with Daiichi Sankyo for ENHERTU®
• Awarded ’10 Million Dollar Export Tower’

2023

• Submission of BLA to MFDS for Tergase®, stand-alone recombinant hyaluronidase product
• Patient enrollment completed in Global Phase 3 trial of Eylea® biosimilar ‘ALT-L9’
• Selected as ‘2023 KOSDAQ Rising Star’ (KRX)
• Submission of IND to DCGI for Phase 2 trial of long-acting human growth hormone ‘ALT-P1’
• Subsidiary ‘Ceres F&D’ merged with ‘LS Meditech’
• Acquired ISO9001 certification for quality management system

2022

• First patient first dosed in Global Phase 3 trial of Eylea® biosimilar ‘ALT-L9’
• Selected as ‘2022 KOSDAQ Rising Star’ (KRX)
• Renewal of Intellectual Property Management Enterprise certification (KIPA)
• CEO Soon Jae Park, PhD Jang Young-shil Award Hall of fame induction
• CEO Soon Jae Park, PhD, Government Award for Promotion of Venture Businesses (Industrial Service Medal)
• Executed Hybrozyme™ Technology license agreement with Sandoz AG for 1 application

2021

• Executed Hybrozyme™ Technology license agreement with Intas Pharmaceuticals
• Altos Biologics, a subsidiary of Alteogen, completed an investment of 60.5 billion won
• Initiated India Phase 1b trial of long-acting human growth hormone ‘ALT-P1’
• Selected as ‘2021 KOSDAQ Rising Star’ (KRX)
• IND application approved by MFDS for Tergase®, stand-alone recombinant hyaluronidase product
• Long-acting acromegaly treatment ‘ALT-B5’ selected for National New Drug Development Project
• Awarded ’2 Million Dollar Export Tower’ (MOTIE)

2020

• IND submission to MFDS for Tergase®, stand-alone recombinant hyaluronidase product
• Awarded ’1 Million Dollar Export Tower’ (MOTIE)
• Completion of patient dosing in Phase 1 trial of Eylea® biosimilar ‘ALT-L9’
• Established subsidiary ‘Altos Biologics’
• Developed ADC breast and gastric cancer treatment-combination
• Eylea® biosimilar ‘ALT-L9’ fusion protein manufacturing method patent granted (KR, JP etc.)
• Completed Korea’s first Phase 1 trial of breast cancer ADC treatment ‘ALT-P7’
• Recombinant hyaluronidase manufacturing method patent application submitted
• Selected as ‘2020 KOSDAQ Rising Star’ (KRX)
• Executed Hybrozyme™ Technology license agreement with Top 10 global pharmaceutical company
• Registered patent for modified antibody conjugated with a motif containing a cysteine residue (Europe)
• Presented ADC breast cancer treatment ‘ALT-P7’ abstract at 2020 ASCO
• Eylea® biosimilar ‘ALT-L9’ formulation patent granted (CA, AU)
• PCT filed for subcutaneous formulation of recombinant hyaluronidase and antibody treatment
• Selected as 2019 excellent corporation for public announcement (KRX)
• First patient first dosed in Phase 1 trial of Eylea® biosimilar ‘ALT-L9’
• Additional patents filed for expanded rights to human hyaluronidase variants

2019

• Executed Hybrozyme™ Technology license agreement with Top 10 global pharmaceutical company
• Executed manufacturing agreement with DM Bio for manufacturing Eylea® biosimilar ‘ALT-L9’
• PCT filed for proprietary technology of recombinant hyaluronidase
• Executed joint-development and technology transfer agreement with Cristália for long-acting human growth hormone ‘ALT-P1’
• Patent granted for ADC treatment (KR)
• Patent granted for Eylea® biosimilar ‘ALT-L9’ fusion protein manufacturing method (KR, JP, AU)
• China IND approved for Herceptin® biosimilar ‘ALT-L2’
• Patent filed for subcutaneous formulation of recombinant hyaluronidase and antibody treatment
• Korea Phase 1 trial IND approved for Eylea® biosimilar ‘ALT-L9’
• Executed Hybrozyme™ Technology option agreement with Top 10 global pharmaceutical company
• Presented ADC breast cancer treatment at 2019 PEGS Boston

2018

• Executed joint development agreement for ADC breast cancer treatment manufacturing with DGMIF
• Presented ADC breast cancer treatment results at World ADC conference
• Awarded grand prize of Korean Biotherapeutics Award
• ADC gastric cancer treatment ‘ALT-P7’ designated as orphan drug (FDA)
• Developed proprietary Hybrozyme™ Technology platform
• Completed Korea Phase 2a trial of long-acting human growth hormone ‘ALT-P1’
• Established subsidiary Ceres F&D
• Selected for the Innovative IP Global Product Commercialization Project for long-acting human growth hormone ‘ALT-P1’ (MOTIE)
• Preclinical studies for Eylea® biosimilar ‘ALT-L9’ completed (US)
• Developed ovarian cancer ADC treatment utilizing NexMab™ Technology
• Selected for the Core Technology Development Project for Bio Industry for long-acting human growth hormone ‘ALT-P1’ (MOTIE)
• Awarded Excellence Award in bioprocessing (Asia-Pacific Bioprocessing Excellence Awards 2018)

2017

• Selected as 2017 Youth-friendly Strong Small Business (MOEL)
• Selected as 2017 Excellent Bio-field Company (MOTIE Award)
• First patient dosed in Korea Phase 2 trial for long-acting human growth hormone ‘ALT-P1’
• Breast cancer ADC treatment selected as Development Project for National New Drug Development Project
• Certified as a venture company (Fifth, Venture Investment Company No. 20170300402)
• First patient dosed in Korea Phase 1 trial for breast cancer ADC treatment ‘ALT-P7’
• Awarded Grand Award at Maekyung Star Audition
• Executed tech transfer agreement for Herceptin® biosimilar ‘ALT-L2’ to Qilu Pharmaceutical
• Selected as Excellent Brainpower Company (MOTIE)

2016

• Completed Canada Phase 1 trial for Herceptin® biosimilar ‘ALT-L2’
• CEO Soon Jae Park, PhD received Intellectual Property Entrepreneur Award (Korea Invention Promotion Association Chairman’s Award)
• Selected as Outstanding Company for Regional Industry Promotion (MOTIE Award)
• Selected as 2016 National R&D Top 100 Excellence Performance (MSIP)
• CEO Soon Jae Park, PhD selected as Honoree for Contributions to the Advancement of the Biopharmaceutical Industry
• NexP™ hemophilia treatment selected as development project by Ministry of Trade, Industry and Energy of Korea
• Selected for the Excellent Brainpower Company Technology Development Project (K-Brain Power)
• Selected as 2016 Youth-friendly Strong Small Business (MOEL)

2015

• Selected as 2015 Excellent Company in Bio field by Ministry of Industry of Korea
• Completed Phase 1 trial of long-acting human growth hormone ‘ALT-P1’
• Certified as a venture company (Fourth, Venture Investment Company No. 20150300299)

2014

• Selected as Excellent Brainpower Company (MOTIE)
• Listed on KOSDAQ
• Selected as IP Star Company (Korean Intellectual Property Office)

2013

• Certified as a venture company (Third, Venture Investment Company No. 20130300194)
• Selected for the Global Strong Small Business Fostering Program by the Small and Medium Business Administration for the development of arthritis treatment antibody biosimilar

2012

• Selected as Outstanding Contributor to Municipal Development
• Selected as military service waived company (Research center affiliated with venture company)
• Subsidiary Altos Bioscience executed a license agreement for animal medicine with Brazil UQ

2011

• Executed license agreement for 1 antibody biosimilar with Brazil Cristália
• Certified as a venture company (Second, Venture Investment Company No. 20110300189)
• Breast cancer ADC treatment selected as Industry Convergence Original Technology Development Project by Ministry of Knowledge Economy of Korea
• Selected as Regional Star Company (MKE)

2010

• CEO Soon Jae Park, PhD received ‘Top 100 Technologies and the People in Republic of Korea’ (NAEK)
• Executed license agreement for long-acting human growth hormone with CJ CheilJedang
• Soon Jae Park, Phd appointed CEO

2009

• Certified as a venture company (First, Venture Investment Company No. 20090107651)
• Research center confirmed (Korea Industrial Technology Association, No. 20092108282)

2008

• R&D department confirmed (Korea Industrial Technology Association, No. 2008250266)
• Established Alteogen